Xenetic Biosciences, Inc. — Q2 2016 Form 10-Q
Business context and reporting period. The clinical-stage biopharmaceutical company reported for the three and six months ended June 30, 2016. Its pipeline and platforms include Virexxa, OncoHist, ErepoXen, PolyXen and ImuXen. No candidate had received regulatory approval, and the company reported no collaboration revenue for the six-month periods in either 2016 or 2015.
Financial results and liquidity
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue | $0 reported | $0 reported | $0 reported | $0 reported |
| Research and development expense | $2.21 million | $0.56 million | $2.63 million | $1.59 million |
| In-process R&D expense | $39.50 million | — | $39.50 million | — |
| General and administrative expense | $1.56 million | $0.80 million | $2.98 million | $1.74 million |
| Net loss | $47.77 million | $1.13 million | $51.34 million | $3.56 million |
| Operating cash used | Not separately stated | Not separately stated | $3.13 million | $2.23 million |
- The $39.5 million IPR&D charge followed the April acquisition of Virexxa rights; it was non-cash and included a $3.74 million prepayment recorded in 2015. The large net loss therefore does not represent equivalent cash burn.
- At June 30, cash was $240,786 and restricted cash was $66,510. Current assets were $478,495 against current liabilities of $3.80 million, a working-capital deficit of approximately $3.32 million. Total liabilities were $6.75 million; stockholders’ equity was $6.41 million.
- Six-month financing cash flow was $3.26 million, including $3.5 million of note proceeds and $242,471 in payments on a related-party loan. Cash rose from $132,229 at year-end to $240,786.
- Gross margin is not applicable because the filing reports no revenue. Cash and restricted cash totaled about $307,000; the filing identifies no conventional ongoing revenue base or meaningful operating margin.
Material changes versus the prior period
- Quarterly net loss rose from $1.13 million to $47.77 million, primarily reflecting the Virexxa IPR&D charge, higher R&D and G&A costs, and debt-related items. Six-month net loss increased from $3.56 million to $51.34 million.
- On April 29, the company closed its Virexxa asset purchase, issued 3,045,455 shares to Pharmsynthez and recorded the $39.5 million expense. The filing describes worldwide development, marketing and licensing rights for specified uses, subject to exclusions.
- Pharmsynthez converted $6.5 million of principal plus accrued interest into 1,373,036 common shares at $4.95 per share. The company also recorded significant derivative and debt-conversion accounting items. The statements report a $6.19 million conversion loss, while a note describes a $4.4 million net loss including a final derivative mark-to-market; the filing text does not clearly reconcile these amounts.
- Common shares outstanding increased to 9,024,872 at June 30 from 4,585,800 at December 31, after a 1-for-33 reverse split and transaction-related share issuance. The company reported 9,024,872 outstanding shares as of August 15.
- Quarterly share-based compensation rose to $1.73 million from $89,970; six-month expense was $2.02 million versus $237,198. The company cites, among other items, Serum warrant issuance and repricing.
Outlook, risks and unusual items
- Management said additional working capital was required to meet obligations over the next 12 months and disclosed substantial doubt about the company’s ability to continue as a going concern without new financing.
- The company was pursuing a public offering and national exchange listing, with a contemplated minimum $8.5 million public offering and a further $6.0 million Pharmsynthez investment. Management described total contemplated financing of $18.5 million, including $4.0 million in APA notes. As of August 15, it reported $4.0 million drawn under those notes and $6.0 million remaining in Pharmsynthez financing commitment; completion and terms were not assured.
- If a national listing and capital raise could not be completed, Pharmsynthez was to provide up to $6.0 million as loans on essentially similar terms to the APA notes. The filing warns this outcome could require further financing or deferred R&D. On July 1, after quarter-end, the company received $0.5 million under the APA financing arrangement.
- The filing states that significant collaboration receipts were not expected within six months and that future Shire payments were contingent on clinical outcomes. Timing and proceeds from planned out-licensing were also uncertain.
- The 10% secured convertible notes were converted to equity in April, removing the recorded hybrid debt balance at June 30, but the company remained highly liquidity-constrained. Related-party obligations and deferred CEO salary warrant attention: on July 1, the company issued the CEO a $369,958 convertible note and warrants for deferred salary, and agreed to continue deferring half his salary until the earlier of a qualifying offering or September 30, 2016.
- Key risks include financing availability, clinical and regulatory development, dependence on collaborators and contingent milestones, competition, intellectual-property claims, and the early-stage status of all drug candidates. Management reported disclosure controls effective at a reasonable-assurance level and no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether the public offering/listing was completed, the amount and terms raised, and whether Pharmsynthez fulfilled its remaining commitment.
- Cash runway, payment obligations, and the status or terms of any further secured or convertible financing.
- The reconciliation and cash/non-cash accounting of the reported debt-conversion loss, including the $6.19 million statement amount versus the $4.4 million note description.
- Virexxa rights acquired, development progress, clinical plans, and the commercial significance and accounting basis of the $39.5 million IPR&D charge.
- Potential dilution from shares, warrants, and convertible or deferred-salary instruments, including the effect of the reverse split and subsequent financing.
- Any subsequent collaboration milestones, out-licensing agreements, or clinical results that could generate cash or materially affect the pipeline outlook.